Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07638007 · ClinicalTrials.gov registry record
Impact of Targeted Therapy on Cancer-Related Cognitive Impairment
A clinical trial, sponsored by University of Rochester NCORP Research Base.
- Recruiting
- Registry status
- 400
- Enrollment target
NCT07638007: Recruiting study, sponsored by University of Rochester NCORP Research Base.
NCT07638007 is a clinical trial that is actively recruiting participants, run by University of Rochester NCORP Research Base. The registered enrollment target is 400 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07638007 is actively recruiting participants, sponsored by University of Rochester NCORP Research Base.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
Study Summary
This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
Primary Outcome
Will be assessed using the FACT-Cog. Will apply multilevel models to study data. Will include main effects of time, group, and the group X time interaction.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2029-02-28 |
What NCT07638007 shows while recruiting
NCT07638007 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07638007 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07638007 about?
NCT07638007 is a clinical study titled "Impact of Targeted Therapy on Cancer-Related Cognitive Impairment". This study examines whether there are differences in brain health or well-being in patients receiving TKI therapy for leukemia compared to individuals who do not receive TKI therapy.
What is the current status of trial NCT07638007?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2025-11-21. Estimated completion is 2029-02-28.
Who is sponsoring clinical trial NCT07638007?
This trial is sponsored by University of Rochester NCORP Research Base, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI